郎胜利, 徐丽娟, 张继薇, 王翠秀. 2015-2020年内蒙古自治区利福平耐药肺结核筛查及患者纳入治疗情况分析[J]. 疾病监测, 2021, 36(10): 1048-1051. DOI: 10.3784/jbjc.202105200280
引用本文: 郎胜利, 徐丽娟, 张继薇, 王翠秀. 2015-2020年内蒙古自治区利福平耐药肺结核筛查及患者纳入治疗情况分析[J]. 疾病监测, 2021, 36(10): 1048-1051. DOI: 10.3784/jbjc.202105200280
Lang Shengli, Xu Lijuan, Zhang Jiwei, Wang Cuixiu. Rifampicin-resistant pulmonary tuberculosis patient screening and treatment in Inner Mongolia, 2015–2020[J]. Disease Surveillance, 2021, 36(10): 1048-1051. DOI: 10.3784/jbjc.202105200280
Citation: Lang Shengli, Xu Lijuan, Zhang Jiwei, Wang Cuixiu. Rifampicin-resistant pulmonary tuberculosis patient screening and treatment in Inner Mongolia, 2015–2020[J]. Disease Surveillance, 2021, 36(10): 1048-1051. DOI: 10.3784/jbjc.202105200280

2015-2020年内蒙古自治区利福平耐药肺结核筛查及患者纳入治疗情况分析

Rifampicin-resistant pulmonary tuberculosis patient screening and treatment in Inner Mongolia, 2015–2020

  • 摘要:
      目的  分析2015 — 2020年内蒙古自治区(内蒙古)利福平耐药肺结核筛查、患者纳入治疗情况及变化趋势,了解其流行现状、特点,探索适合当地的耐药肺结核防治相关政策。
      方法  收集2015 — 2020年内蒙古肺结核患者病案及利福平耐药筛查、患者纳入治疗等资料,数据均来源于“结核病管理信息系统”。 采用率及构成比进行描述性统计分析。
      结果  2015 — 2020年内蒙古肺结核新病原学阳性患者耐药筛查率为60.7%,高危人群耐药筛查率为72.2%,新病原学阳性患者及高危人群耐药筛查率均逐年升高(趋势χ2=36625,P<0.0001;趋势χ2=6 465,P<0.0001);不同登记分类肺结核患者耐药检出率为9.7%,其中新病原学阳性患者检出率为6.0%,高危人群检出率为22.3%,明显高于新患者检出率(趋势χ2=13 293,P<0.0001),检出率以复治失败患者最高(50.0%);新病原学阳性耐药患者纳入治疗率为66.1%,高危人群耐药患者纳入治疗率为70.9%,且逐年提高(趋势χ2=928,P<0.0001,趋势χ2=1 095,P<0.0001)。
      结论  内蒙古地区肺结核病原学阳性患者耐药筛查率、纳入治疗率逐年提高。

     

    Abstract:
      Objective  To understand the screening and treatment of rifampicin-resistant pulmonary tuberculosis (TB) patients in Inner Mongolia autonomous region from 2015 to 2020 and provide evidence for the development of local drug-resistant TB prevention and treatment strategies.
      Methods  The medical records of TB patients and the data of rifampicin resistant pulmonary TB patient screening and treatment in Inner Mongolia from 2015 to 2020 were collected from “Tuberculosis Information Management System”, the rate and composition ratio were used for descriptive statistical analysis.
      Results  The screening rate of rifampicin resistance was 60.7% in new pathogenic positive pulmonary TB patients and 72.2% in high-risk group in Inner Mongolia during 2015–2020, and the rifampicin resistance screening rates increased year by year (trend χ2=36625, P<0.0001; trend χ2=6465, P<0.0001); The detection rate of rifampicin resistance in pulmonary TB patients with different registration classification was 9.7%. The detection rate in new pathogenic positive pulmonary TB patients was 6.0%, and the detection rate in high-risk group was 22.3%, higher than that in new pathogenic positive pulmonary TB patients (trend χ2=13293, P<0.0001). The detection rate was highest in the patients with failed treatment (50.0%); The rate of treatment of rifampicin-resistant patients was 66.1% in new pathogenic positive pulmonary TB patients and 70.9% in high-risk group, and the annual rate increased year by year (trend χ2=928, P<0.0001, trend χ2=1095, P<0.0001).
      Conclusion  The rate of rifampicin resistance screening and the rate of treatment in pathogenic positive  pulmonary TB patients in Inner Mongolia increased year by year.

     

/

返回文章
返回